Dainippon Sumitomo Changes Drug Name To Avoid Misuse
This article was originally published in PharmAsia News
Dainippon Sumitomo Pharma has submitted an application to change the name of hypertension drug Almarl (arotinolol) with the Ministry of Health, Labor and Welfare.
You may also be interested in...
The proposed rule from the US HHS that would require its agencies to review all regulations every 10 years could distract an incoming Biden administration from the COVID-19 pandemic and will “wreak havoc” on Medicare, a senior policy analyst for the Center on Budget and Policy Priorities says.
The pharmacy will be ready to begin COVID-19 vaccinations 48 hours after receiving the vaccine, Merlo said, outlining plans for a mass vaccination effort that will include online appointments.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.